Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 13;33(3):568–576. doi: 10.1111/jdv.15292

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Mean PASI (a), DLQI (b) and PSSI (c) data (up to at least 120 weeks from the start of retreatment). Data, including the Induction Dosing Period, are from PASI75 responders at Week 52. The number of patients at selected weeks is shown below each graph. DLQI, Dermatology Life Quality Index; IXE, ixekizumab; IXE Q2W, 80 mg ixekizumab every 2 weeks; IXE Q4W, 80 mg ixekizumab every 4 weeks; PASI, Psoriasis Area Severity Index; PASI75, ≥75% improvement in the Psoriasis Area Severity Index; PSSI, Psoriasis Scalp Severity Index.